Zenith Epigenetics Announces Dosing of First mCRPC Patient with a Combination of ZEN-3694 + Merck’s Immune Check Point Inhibitor KEYTRUDA
ZEN-3694, the Companys lead therapeutic compound, is being developed for epigenetic combination therapies in multiple oncology indications.
- ZEN-3694, the Companys lead therapeutic compound, is being developed for epigenetic combination therapies in multiple oncology indications.
- This clinical trial will evaluate the aforementioned triple combination therapy in mCRPC patients that have become resistant to a 1stline ARSI therapy.
- Zenith Capital Corp. is a biotechnology investment company originally spun out of Resverlogix Corp. (TSX: RVX) in 2013.
- The lead compound, ZEN-3694, is in clinical development for:
Metastatic Castration Resistant Prostate Cancer (mCRPC) in combination with androgen receptor inhibitor, XTANDI